WHO & Regional Offices [to 12 Oct 2019]

WHO & Regional Offices [to 12 Oct 2019]
10 October 2019
News release
WHO welcomes vital new funding for the Global Fund

10 October 2019
News release
The use of non-pharmaceutical forms of Artemisia
Today, the most widely used antimalarial treatments, artemisinin-based combination therapies (ACTs), are produced using the pure artemisinin compound extracted from plant Artemisia annua. Currently, all malaria strains globally can be treated with at least one of the ACTs recommended by WHO.
However, for those living in malaria-affected areas, ACTs are not always readily accessible. In some countries, the medicines are only available at high prices or are of sub-standard quality. These challenges have given rise to the promotion of a range of products made from Artemisia plant material – such as teas, tablets and capsules – as affordable and effective medicines against malaria.
Traditional herbal remedies have several limitations, especially when used to treat potentially fatal diseases such as malaria. The main limitations are related to standardization of plant cultivation, the preparation of formulations, dosages, quality assurance, and evidence of clinical safety and efficacy.
WHO position 
Following an extensive evidence review on the effectiveness of non-pharmaceutical forms of Artemisia, conducted in 2019, WHO has issued a new position statement on this issue with a clear message:
WHO does not support the promotion or use of Artemisia plant material in any form for the prevention or treatment of malaria…

9 October 2019
News release
New evidence shows significant mistreatment of women during childbirth

8 October 2019
News release
WHO launches first World report on vision



Weekly Epidemiological Record, 11 October 2019, vol. 94, 41 (pp. 457–470)
:: Global programme to eliminate lymphatic filariasis: progress report, 2018
:: Monthly report on dracunculiasis cases, January-August 2019



WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: WHO in Africa offers small research grants on the innovative use of GIS towards polio eradication… 11 October 2019
:: [DRC] Parents rush to get measles vaccine after recent outbreak kills thousands of childre…
10 October 2019

WHO Region of the Americas PAHO
:: Ministries of Health from across the Caribbean meet to discuss urgent need to fund health and climate change initiatives (10/08/2019)

WHO South-East Asia Region SEARO
No new digest content identified.

WHO European Region EURO
No new digest content identified.

WHO Eastern Mediterranean Region EMRO
No new digest content identified.

WHO Western Pacific Region
:: 11 October 2019 News release
Region’s leaders discuss need to protect health in relation to climate change and the environment

10 October 2019 News release
Region’s health leaders pledge to tackle antimicrobial resistance and strengthen tobacco control

9 October 2019 News release
Regional action to protect children from harmful impact of food marketing and promote healthy ageing

8 October 2019 News release
Health ministers endorse WHO five-year plan to make the Western Pacific the healthiest, safest region

CDC/ACIP [to 12 Oct 2019]

CDC/ACIP [to 12 Oct 2019]
Latest News
Transcript: Vital Signs – Maternal Vaccination
Wednesday, October 9, 2019

Low Rates of Vaccination During Pregnancy Leave Moms, Babies Unprotected
Nearly half of U.S. newborns and new moms at risk of influenza or whooping cough hospitalization or death
Tuesday, October 8, 2019
The majority of mothers-to-be in the United States – 65% – have not received two safe and effective vaccines recommended during pregnancy to reduce the risks of influenza (flu) and whooping cough (pertussis) and protect their infants and themselves, according to a new Vital Signs report released today by the Centers for Disease Control and Prevention (CDC).
When pregnant women are vaccinated they pass on antibodies to the fetus that provide protection after birth, during the time babies are too young to be vaccinated. Newborns who get influenza or whooping cough are at high risk of hospitalization and death.
And the benefits are not just for the babies. Pregnant women have more than double the risk of hospitalization compared to nonpregnant women of childbearing age if they get influenza. Since 2010, among women ages 15 to 44 years who were hospitalized for influenza, 24% to 34% of them were pregnant – even though only approximately 9% of U.S. women in this age group are pregnant at any given time each year.
CDC recommends that all pregnant women should get a flu vaccine during any trimester of each pregnancy and the whooping cough vaccine (Tdap) during the early part of the third trimester of each pregnancy as part of routine prenatal care…

MMWR News Synopsis for October 11, 2019
Update: Influenza Activity – United States and Worldwide, May 19–September 28, 2019 and Composition of the 2020 Southern Hemisphere Influenza Vaccine
Low levels of influenza activity were reported in the United States over summer 2019, with cocirculation of influenza A and influenza B viruses. In early October 2019, it is too early in the season to know which viruses will circulate in the U.S. later this fall and winter or how severe the season may be. Regardless of what is circulating, the best protection against influenza is a flu vaccination. CDC recommends that everyone 6 months and older get vaccinated against flu. As the 2019-2020 flu season begins, CDC is reporting influenza activity in the United States and the Southern Hemisphere during the U.S. summer months and the vaccine viruses selected for the 2020 Southern Hemisphere influenza vaccines. During the summer months in the U.S., influenza activity remained low as is typical for that time of year. Influenza A and B viruses circulated widely in the Southern Hemisphere with the predominant virus varying by region and country. While influenza is unpredictable and circumstances can change very quickly, data to date continue to support the appropriateness of the recommended composition of the vaccines for the upcoming 2019-2020 season in the United States.
Vital Signs: Burden and Prevention of Influenza and Pertussis Among Pregnant Women and Infants — United States

National Update on Measles Cases and Outbreaks:
National Update on Measles Cases and Outbreaks — United States, January 1–October 1, 2019




Paul G. Allen Frontiers Group [to 12 Oct 2019]
No new digest content identified.


BMGF – Gates Foundation [to 12 Oct 2019]
No new digest content identified.


Bill & Melinda Gates Medical Research Institute [to 12 Oct 2019]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.


CARB-X [to 12 Oct 2019]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.


CEPI – Coalition for Epidemic Preparedness Innovations [to 12 Oct 2019]
No new digest content identified.


Clinton Health Access Initiative, Inc. (CHAI) [to 12 Oct 2019]
News & Press Releases
No new digest content identified.


EDCTP [to 12 Oct 2019]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.


Emory Vaccine Center [to 12 Oct 2019]
No new digest content identified.


European Medicines Agency [to 12 Oct 2019]
No new digest content identified.


European Vaccine Initiative [to 12 Oct 2019]
07 October 2019
EVI and Hilleman Laboratories announce partnership to assess a new vaccine against Shigella
Funding from EDCTP will allow testing of a novel whole-cell inactivated oral vaccine in clinical trials in Europe and Africa…


FDA [to 12 Oct 2019]
October 10, 2019 – FDA allows marketing of first rapid diagnostic test for detecting Ebola virus antigens
Today, the U.S. Food and Drug Administration allowed marketing of a rapid diagnostic test (RDT) to detect Ebola virus antigens (proteins) in human blood from certain living individuals and samples from certain recently deceased individuals suspected to have died from Ebola (cadaveric oral fluid). The OraQuick Ebola Rapid Antigen Test is the first rapid diagnostic test the FDA has allowed to be marketed in the U.S. for the Ebola Virus Disease (EVD). The test provides a rapid, presumptive diagnosis that must be confirmed.
“Today’s marketing authorization provides another important tool in the effort to fight Ebola, which continues to be a priority of the U.S. Government, especially as we work with our partners, including the World Health Organization, to help address the current Ebola outbreak in the Democratic Republic of Congo (DRC),” said Acting FDA Commissioner Ned Sharpless, M.D. “The current outbreak in the DRC has already killed thousands and the outbreaks in West Africa that began in 2014 tragically killed more than 11,000. Investigational vaccines and therapeutics have shown promising results, but one of the most important tools in stopping these outbreaks is quickly diagnosing patients and supporting safe and dignified burials. This marketing authorization may provide additional assurances to health care professionals seeking to use these types of rapid diagnostics. The ability to use this test to promptly make a presumptive Ebola diagnosis could help providers to more quickly isolate patients and begin treatments that can be potentially life-saving. Additionally, this device could be used to support safe and dignified burials while helping to reduce the risk of transmission during those burials.”…

October 8, 2019 – FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases
The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $15 million over the next four years to enhance the development of medical products for patients with rare diseases. The grants were awarded to principal investigators from academia and industry across the country.
The FDA awarded the grants through the Orphan Products Clinical Trials Grants Program, funded by Congress to encourage clinical development of drugs, biologics, medical devices and medical foods for the treatment of rare diseases. The grants are intended to substantially contribute to marketing approval of products to treat rare diseases or provide essential data needed for development of such products…


Fondation Merieux [to 12 Oct 2019]
The Agence Française de Développement and the Mérieux Foundation continue their commitment to strengthen the West African Network of Clinical Laboratories (RESAOLAB)
October 10, 2019, Lyon (France)
Rémy Rioux, Director General of the Agence Française de Développement (AFD), today signed a project with Jean-Pierre Bosser, Director General of the Mérieux Foundation, to develop more efficient and reliable laboratory services in West Africa. Strengthening clinical diagnostics is a central public health issue in West Africa. This RESAOLAB project will receive a total of €8.6 million.

Support for Laboratories
The Mérieux Foundation takes action in response to the Ebola emergency in the Democratic Republic of the Congo
October 8, 2019, Lyon (France)
An Antonov airplane hired specially by the Mérieux Foundation will take off from the Lyon-Saint Exupery airport (France) on Wednesday October 9. Three container laboratories have been loaded onto the aircraft to bolster efforts to control the Ebola virus disease epidemic. Their final destination is Goma, Democratic Republic of the Congo.


Gavi [to 12 Oct 2019]
Latest news
Gavi congratulates Global Fund on successful replenishment 
10 October 2019


GHIT Fund [to 12 Oct 2019]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.


Global Fund [to 12 Oct 2019]
News & Stories
Sixth Replenishment Conference Pledges
11 October 2019

Feature Story
US$14 Billion to Step Up the Fight Against the Epidemics
10 October 2019

Global Fund Donors Pledge US$14 Billion in Fight to End Epidemics
10 October 2019
[See Milestones above for detail]

Private Sector Partners Step Up the Fight to End AIDS, TB and Malaria
09 October 2019

Denmark Increases Pledge in Fight Against Epidemics
07 October 2019


Hilleman Laboratories [to 12 Oct 2019]
Date: 07/10/2019
EVI and Hilleman Laboratories announce partnership to assess a new vaccine against Shigella


Human Vaccines Project [to 12 Oct 2019]
Press Releases
No new digest content identified.


IAVI [to 12 Oct 2019]
No new digest content identified.



International Coalition of Medicines Regulatory Authorities (ICMRA)
Selected Statements, Press Releases, Research
No new digest content identified.



No new digest content identified.


IFRC [to 12 Oct 2019]
Selected Press Releases, Announcements
No new digest content identified.


IVAC [to 12 Oct 2019]
No new digest content identified.


IVI [to 12 Oct 2019]
Selected IVI News & Announcements
No new digest content identified.


JEE Alliance [to 12 Oct 2019]
Selected News and Events
No new digest content identified.


MSF/Médecins Sans Frontières [to 12 Oct 2019]
Latest [Selected Announcements]
TB drug delamanid must be more affordable and made available in more countries
Statement 10 Oct 2019

Access to medicines
MSF demands Johnson & Johnson reduce price of lifesaving TB drug
Press Release 10 Oct 2019

Democratic Republic of Congo
Ebola response overshadows already fragile health system
Project Update 9 Oct 2019

DRC Ebola outbreaks
Crisis update – October 2019
Crisis Update 7 Oct 2019


National Vaccine Program Office – U.S. HHS [to 12 Oct 2019]
Request for Information (RFI) From Non-Federal Stakeholders: Developing the 2020 National Vaccine Plan
For nearly a decade the 2010 National Vaccine Plan (NVP) has served as the nation’s leading roadmap for enhancing all aspects of the U.S. vaccine and immunization system. To ensure the NVP remains nimble to the evolving vaccine and immunization landscape, the U.S. Department of Health and Human Services (HHS) is leading the development of the 2020 National Vaccine Plan. The updated plan will reflect immunization across the lifespan and guide priority actions for the period 2020-2025.
As part of that process, the HHS Office of Infectious Disease and HIV/AIDS Policy (OIDP) has issued a Request for Information to solicit input from subject matter experts and non-federal stakeholders on potential priorities, goals, and objectives for the plan.
We invite you to share your feedback on the Request for Information. Comments are due no later than 5:00 p.m., ET on October 24, 2019.
View the Request for Information and provide your feedback


NIH [to 12 Oct 2019]
Selected News Releases
NIH strategic research plan addresses growing tickborne diseases threat
October 10, 2019 — The incidence of reported cases of tickborne diseases in the United States has significantly increased in recent years.

NIH grantees win 2019 Nobel Prize in Physiology or Medicine
October 7, 2019 — NIH grantees Gregg L. Semenza, M.D., Ph.D. and William G. Kaelin Jr., M.D., win 2019 Nobel in Physiology and Medicine.


PATH [to 12 Oct 2019]
Selected Announcements
PATH celebrates Global Fund’s replenishment and applauds focus on innovation
October 11, 2019 by PATH
Yesterday the world witnessed an unprecedented display of global unity in the fight against HIV/AIDS, TB, and malaria. Countries, companies, philanthropic organizations, and individuals answered the Global Fund’s call to commit US$14 billion over the next three years. This is the largest 3-year resource envelope the Global Fund to Fight AIDS, Tuberculosis and Malaria has ever received.
PATH applauds everyone involved for making this commitment, especially during these challenging economic times. In particular, we recognize the bipartisan US Congressional delegation for committing $1.56 billion per year in financing to the Global Fund—the first increase in US contribution in six years. The generosity of this commitment means the US will reach its target of providing one third of the Global Fund’s resources. This is truly global health leadership in action…


Sabin Vaccine Institute [to 12 Oct 2019]
Statements and Press Releases
No new digest content identified.


UNAIDS [to 12 Oct 2019]
Selected Press Releases/Reports/Statements
11 October 2019
Empowering young Brazilians to talk to their peers about HIV

9 October 2019
UNAIDS and Luxembourg―working together in western and central Africa

7 October 2019
Criminalization of same-sex sexual relationships decreasing


UNICEF [to 12 Oct 2019]
Selected Statements, Press Releases, Reports
Vaccination campaign against cholera kicks off in Sudan
Joint statement by the Sudan Federal Ministry of Health, WHO and UNICEF
[See Milestones above for detail]

Press release
As measles deaths in the Democratic Republic of the Congo top 4,000, UNICEF rushes medical kits to health centers and vaccinates thousands more children
[See Emergencies above for detail]

Press release
UNICEF launches Cryptocurrency Fund
UN Children’s agency becomes first UN Organization to hold and make transactions in cryptocurrency

Press release
As cholera continues to spread, UNICEF charters 1.6 million doses of vaccines to Sudan


Vaccination Acceptance Research Network (VARN) [to 12 Oct 2019]
No new digest content identified.


Vaccine Confidence Project [to 12 Oct 2019]
Confidence Commentary:
Article of the week on “The life-course approach to vaccination”
Heidi Larson | 6 Oct, 2019
An important article mapping the way forward for how vaccines can keep us healthy throughout life. –HL
The life-course approach to vaccination: Harnessing the benefits of vaccination throughout life
Jody Tate, et al.  Published in VACCINE  , 16 October 2019


Vaccine Education Center – Children’s Hospital of Philadelphia [to 12 Oct 2019]
No new digest content identified.


Wellcome Trust [to 12 Oct 2019]
Q&A | 9 September 2019
What are drug-resistant infections?
The overuse of antibiotics is causing one of the most urgent global health problems. In this Q&A we explain what drug-resistant infections are, who is affected and what we can do to stem the rise and spread of drug-resistant infections.

Opinion | 7 October 2019
We hail individual geniuses, but success in science comes through collaboration
Jeremy Farrar, Director Wellcome
The Nobel prizes give a human face to science. But does celebrating individuals risk undermining what’s achieved through a collaborative research culture?

News | 7 October 2019
Nobel prize awarded to Wellcome-funded researcher
Professor Sir Peter Ratcliffe, a researcher at the University of Oxford and the Francis Crick Institute, has been awarded a Nobel prize in physiology or medicine.


Why We Vaccinate [to 12 Oct 2019]
No new digest content identified.


The Wistar Institute [to 12 Oct 2019]
Press Release Oct. 9, 2019
New mechanism fueling brain metastasis discovered at Wistar
The pro-metastatic effect of astrocytes is mediated by activation of the PPAR-gamma pathway in invaded cancer cells and uncovers new use for PPAR-gamma antagonists in cancer therapy.


World Organisation for Animal Health (OIE) [to 12 Oct 2019]
No new digest content identified.





ARM [Alliance for Regenerative Medicine] [to 12 Oct 2019]
No new digest content identified.


BIO [to 12 Oct 2019]
Oct 8 2019
Biotechnology Innovation Organization Announces 2021 Leadership Transition
The Biotechnology Innovation Organization (BIO) today announced that industry veteran Jim Greenwood will step down as President and CEO of the world’s largest biotechnology organization after the 2020 election and help transition a new leader to represent the industry globally and to defend innovation from domestic political attacks.


DCVMN – Developing Country Vaccine Manufacturers Network [to 12 Oct 2019]
DCVMN 20th Annual General Meeting
21 October 2019 to 23 October 2019
Rio de Janeiro / Brazil

12 October 2019
A new Measles-Rubella vaccine prequalified by WHO: Another affordable option for vaccine supply
Geneva, 29 September 2019 – A new measles-rubella (MR) vaccine has been prequalified by the World Health Organization (WHO) Biological E (BioE), a leading vaccine manufacturer in India, thanks to a partnership with PATH. Like measles, rubella is known for the long-term health consequences it can wreak on children less than five years old. Given the high risk of death or debilitating complications malnourished children face, the WHO recommends tackling these illnesses together with the MR vaccine. Unfortunately, adequate supply is a challenge….


IFPMA [to 12 Oct 2019]
Selected Press Releases, Statements, Publications
No new digest content identified.


PhRMA [to 12 Oct 2019]
Selected Press Releases, Statements
October 10, 2019
What They Are Saying: Broad Opposition to Pelosi’s Radical Drug Pricing Plan
Tom Wilbur


Industry Watch [to 12 Oct 2019]
:: Boehringer Ingelheim Completes Plant Expansion After $76 Million Georgia Investment
The company doubled its capacity to produce pet vaccines in Athens, Ga.
Oct. 9, 2019
…”Today’s announcement is representative of the growth and investment Boehringer Ingelheim is making around the United States. It also signals our commitment to a world in which no animal suffers from a preventable disease,” said Everett Hoekstra, president of Boehringer Ingelheim Animal Health USA Inc. “We are excited about what’s in store for our company and our communities, and for the future of animal health.”…

Journal Watch

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focu-s on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org